Endoscopic eradication therapy for patients with Barrett’s esophagus–associated dysplasia and intramucosal cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Barrett’s esophagus (BE) is defined by the replacement of the normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.1-3 BE is an adverse event of chronic GERD and the only identifiable premalignant condition for esophageal adenocarcinoma (EAC), a cancer that continues to increase in incidence. In 2014 there were approximately 18,170 incident cases of esophageal cancer in the United States, nearly 60% of which were EAC.4-6 Although uncommon, EAC is a highly lethal cancer associated with a poor 5-year survival rate of 15% to 20% and an overall median survival of <1 year in cases with advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
The Vienna classification of gastrointestinal epithelial neoplasia
Schlemper, R. J., Riddell, R. H., Kato, Y., Borchard, F., Cooper, H. S., Dawsey, S. M., Dixon, M. F., Fenoglio-Preiser, C. M., Fléjou, J.-F., Geboes, K., et al. (2000) · Gut · doi:10.1136/gut.47.2.251 · Cited by 2,138 · cited 1×
“Organization classification of GI tumors are the grading systems used to categorize the grade of dysplasia in BE patients.(35,36) Significant interobserver and intraobserver variability has been well described among community and expert pathologists, especially regarding the diagnosis of LGD.”
MethodACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,501 · cited 15×
“Surveillance intervals suggested by current guidelines are largely driven by expert opinion and low quality evidence.(2,14) An initial endoscopic examination at 3 to 6 months after CE-IM is achieved is suggested followed by surveillance intervals based on pretreatment histology.”
BackgroundMethodResultInfluentialRadiofrequency Ablation in Barrett's Esophagus with Dysplasia
Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., Galanko, J. A., Bronner, M. P., Goldblum, J. R., Bennett, A. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808145 · Cited by 1,438
Incidence of Adenocarcinoma among Patients with Barrett's Esophagus
Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sørensen, H. T., & Funch-Jensen, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103042 · Cited by 1,371
Pohl, H., & Welch, H. G. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji024 · Cited by 1,270
American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.031 · Cited by 1,060
(2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.030 · Cited by 1,009
Prevalence of Barrett’s Esophagus in the General Population: An Endoscopic Study
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S., Lind, T., Bolling–Sternevald, E., Vieth, M., Stolte, M., Talley, N. J., & Agréus, L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.053 · Cited by 940 · cited 1×
“It is estimated that BE is present in 1% to 2% of the general adult population.(8,9) The stepwise and hypothesized progression of BE to invasive EAC is believed to occur through the histopathologic stages of intestinal metaplasia to low-grade dysplasia (LGD) to high-grade dysplasia (HGD) to intramucosal EAC and finall…”
BackgroundReproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
Montgomery, E., Bronner, M. P., Goldblum, J. R., Greenson, J. K., Haber, M. M., Hart, J., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D. N., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.23510 · Cited by 823
Pech, O., Behrens, A., May, A., Nachbar, L., Gossner, L., Rabenstein, T., Manner, H., Guenter, E., Huijsmans, J., Vieth, M., et al. (2008) · Gut · doi:10.1136/gut.2007.142539 · Cited by 678 · cited 1×
“4 : 2018 search, 17 reviewed in full text format and 2 studies met inclusion criteria).(19,62) Supplementary Table 2 (available online at www.”
BackgroundPhoa, K. N., van Vilsteren, F. G. I., Weusten, B. L. A. M., Bisschops, R., Schoon, E. J., Ragunath, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., et al. (2014) · JAMA · doi:10.1001/jama.2014.2511 · Cited by 640
Overholt, B. F., Lightdale, C. J., Wang, K. K., Canto, M. I., Burdick, S., Haggitt, R. C., Bronner, M. P., Taylor, S. L., Grace, M. G. A., & Depot, M. (2005) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.06.047 · Cited by 527
Trends in esophageal adenocarcinoma incidence and mortality
Hur, C., Miller, M., Kong, C. Y., Dowling, E. C., Nattinger, K. J., Dunn, M., & Feuer, E. J. (2013) · Cancer · doi:10.1002/cncr.27834 · Cited by 507
Pech, O., May, A., Manner, H., Behrens, A., Pohl, J., Weferling, M., Hartmann, U., Manner, N., Huijsmans, J., Gossner, L., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.006 · Cited by 499 · cited 2×
“The safety of EMR in BE patients has been established in multiple studies.(22,56,57) In a cohort study of 681 patients treated at a tertiary care center, a total of 1388 endoscopic procedures were performed, and 2513 EMRs were performed using the cap or multiband mucosectomy technique.”
BackgroundZagari, R. M., Fuccio, L., Wallander, M.-A., Johansson, S., Fiocca, R., Casanova, S., Farahmand, B. Y., Winchester, C. C., Roda, E., & Bazzoli, F. (2008) · Gut · doi:10.1136/gut.2007.145177 · Cited by 481 · cited 1×
“It is estimated that BE is present in 1% to 2% of the general adult population.(8,9) The stepwise and hypothesized progression of BE to invasive EAC is believed to occur through the histopathologic stages of intestinal metaplasia to low-grade dysplasia (LGD) to high-grade dysplasia (HGD) to intramucosal EAC and finall…”
BackgroundLow-Grade Dysplasia in Barrett's Esophagus: Overdiagnosed and Underestimated
Curvers, W. L., ten Kate, F. J., Krishnadath, K. K., Visser, M., Elzer, B., Baak, L. C., Bohmer, C., Mallant-Hent, R. C., van Oijen, A., Naber, A. H., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.171 · Cited by 463
Bennett, C., Vakil, N., Bergman, J., Harrison, R., Odze, R., Vieth, M., Sanders, S., Gay, L., Pech, O., Longcroft–Wheaton, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.032 · Cited by 375 · cited 1×
“However, this treatment approach is associated with an operative mortality of 2% and a high morbidity rate seen even at high-volume centers.(48,49) The basic premise of EET is that BE patients with HGD and intramucosal EAC have a very low risk of lymph node metastasis (0% in patients with HGD and up to 2% in patients…”
BackgroundEpidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma
Rubenstein, J. H., & Shaheen, N. J. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.053 · Cited by 364
Orman, E. S., Li, N., & Shaheen, N. J. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.03.039 · Cited by 296
Continuing Rapid Increase in Esophageal Adenocarcinoma in England and Wales
Lepage, C., Rachet, B., Jooste, V., Faivre, J., & Coleman, M. P. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02191.x · Cited by 263
Risk Factors for Progression of Low-Grade Dysplasia in Patients With Barrett's Esophagus
Wani, S., Falk, G. W., Post, J., Yerian, L., Hall, M., Wang, A., Gupta, N., Gaddam, S., Singh, M., Singh, V., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.055 · Cited by 253 · cited 6×
“As described above, there is evidence across multiple studies and various outcomes that review by an expert www.giejournal.org pathologist or panel of pathologists affects outcomes in patients with BE, especially in BE patients with LGD.”
BackgroundInfluentialSelf-citationLeers, J. M., DeMeester, S. R., Oezcelik, A., Klipfel, N., Ayazi, S., Abate, E., Zehetner, J., Lipham, J. C., Chan, L., Hagen, J. A., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3181fbad42 · Cited by 251 · cited 1×
“Esophagectomy is considered as the treatment of choice for patients with submucosal cancer (T1b sm2-3 disease), poorly differentiated cancer, and cancer associated with lymphatic or vascular infiltration given the high risk of lymph node metastasis (at least 20%).(2,23,55) Long-term survival data in patients undergoin…”
BackgroundPhoa, K. N., Pouw, R. E., van Vilsteren, F. G. I., Sondermeijer, C. M. T., Ten Kate, F. J. W., Visser, M., Meijer, S. L., van Berge Henegouwen, M. I., Weusten, B. L. A. M., Schoon, E. J., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.046 · Cited by 246
Dunbar, K. B., & Spechler, S. J. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.78 · Cited by 240
Wani, S., Falk, G., Hall, M., Gaddam, S., Wang, A., Gupta, N., Singh, M., Singh, V., Chuang, K., Boolchand, V., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.11.008 · Cited by 235
Self-citationQumseya, B. J., Wani, S., Desai, M., Qumseya, A., Bain, P., Sharma, P., & Wolfsen, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.001 · Cited by 175 · cited 15×
“Recurrence of intestinal metaplasia or neoplasia is defined by the presence of intestinal metaplasia on surveillance biopsy specimens in the presence or absence of endoscopically visible BE after achieving CE-IM.(22) Although the number of endoscopies with negative biopsy specimens required to achieve CE-IM is not sta…”
BackgroundMethodInfluentialSelf-citationVennalaganti, P., Kanakadandi, V., Goldblum, J. R., Mathur, S. C., Patil, D. T., Offerhaus, G. J., Meijer, S. L., Vieth, M., Odze, R. D., Shreyas, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.041 · Cited by 167
The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus
Hur, C., Choi, S. E., Rubenstein, J. H., Kong, C. Y., Nishioka, N. S., Provenzale, D., & Inadomi, J. M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.010 · Cited by 155 · cited 2×
“Costeffectiveness analyses, described earlier, clearly demonstrate that among BE patients with HGD, RFA was more effective and less costly than endoscopic surveillance.(30)”
BackgroundDesai, M., Saligram, S., Gupta, N., Vennalaganti, P. R., Bansal, A. K., Choudhary, A., Vennelaganti, S., He, J., Titi, M. A., Maselli, R., et al. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.09.022 · Cited by 153
Self-citationWani, S., Drahos, J., Cook, M. B., Rastogi, A., Bansal, A., Yen, R., Sharma, P., & Das, A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.08.002 · Cited by 113 · cited 12×
“The benefits include reduction in the risk of metachronous neoplasia 924 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 4 : 2018 and thus the potential to reduce the risk of progression to invasive EAC.”
BackgroundMethodResultInfluentialSelf-citationRisk of recurrence of Barrett’s esophagus after successful endoscopic therapy
Krishnamoorthi, R., Singh, S., Ragunathan, K., Katzka, D. A., Wang, K. K., & Iyer, P. G. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.02.009 · Cited by 113 · cited 2×
“Recurrence of intestinal metaplasia and neoplasia after EET was addressed in 2 recent systematic reviews and meta-analyses.(51,52) These studies demonstrated that >95% of all recurrences were successfully treated with EET, adding credence to use of EET for”
BackgroundThe AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence
Sultan, S., Falck–Ytter, Y., & Inadomi, J. M. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.001 · Cited by 104 · cited 2×
“It includes a systematic review of available literature along with guidelines for EET in the management of BErelated dysplasia and intramucosal EAC patients, developed using the GRADE framework.(24) After evidence synthesis, recommendations were drafted by the full panel during a face-to-face meeting on March 23, 2017…”
MethodSelf-citationQumseya, B. J., Wani, S., Gendy, S., Harnke, B., Bergman, J. J. G. H. M., & Wolfsen, H. C. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.70 · Cited by 101 · cited 1×
“The evidence for these outcomes was informed by 2 recent systematic reviews (see Table 6).(22,33) Qumseya et al(33) conducted a systematic review and meta-analysis comparing the risk of progression to HGD/EAC among BE patients with LGD treated with RFA compared with surveillance endoscopy using data from 22 studies of…”
MethodSelf-citationEndotherapy versus surgery for early neoplasia in Barrett's esophagus: a meta-analysis
Wu, J., Pan, Y., Wang, T., Gao, D., & Hu, B. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.08.005 · Cited by 93
Sharma, P., Katzka, D. A., Gupta, N., Ajani, J. A., Buttar, N. S., Chak, A., Corley, D. A., El‐Serag, H. B., Falk, G. W., Fitzgerald, R. C., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.007 · Cited by 92
Safety of Endoscopic Mucosal Resection for Barrett's Esophagus
Tomizawa, Y., Iyer, P. G., Song, L. M. W. K., Buttar, N. S., Lutzke, L. S., & Wang, K. K. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.187 · Cited by 75 · cited 2×
“The safety of EMR in BE patients has been established in multiple studies.(22,56,57) In a cohort study of 681 patients treated at a tertiary care center, a total of 1388 endoscopic procedures were performed, and 2513 EMRs were performed using the cap or multiband mucosectomy technique.”
MethodWani, S. B., Muthusamy, V. R., Shaheen, N. J., Yadlapati, R. H., Wilson, R., Abrams, J. A., Bergman, J. J. G. H. M., Chak, A., Chang, K. J., Das, A., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.03.010 · Cited by 60 · cited 18×
“Surveillance intervals suggested by current guidelines are largely driven by expert opinion and low quality evidence.(2,14) An initial endoscopic examination at 3 to 6 months after CE-IM is achieved is suggested followed by surveillance intervals based on pretreatment histology.”
BackgroundMethodResultInfluentialSelf-citationWani, S. B., Muthusamy, R. V., Shaheen, N. J., Yadlapati, R. H., Wilson, R., Abrams, J. A., Bergman, J. J. G. H. M., Chak, A., Chang, K. J., Das, A., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.166 · Cited by 60 · cited 12×
“This recommendation was also recently included as 1 of the ASGE and American College of Gastroenterology endorsed quality indicators for EET in BE.14,41 Question 2a: Comparing EET with surveillance, what is the optimal management strategy in BE patients with LGD?”
BackgroundResultInfluentialSelf-citationRosmolen, W. D., Boer, K. R., de Leeuw, R., Gamel, C. J., Henegouwen, M. I. V. B., Bergman, J. J. G. H. M., & Sprangers, M. A. G. (2010) · Endoscopy · doi:10.1055/s-0029-1244222 · Cited by 48 · cited 1×
“As highlighted earlier, a study assessing the influence of EET and esophagectomy on quality of life showed that patients undergoing EET reported a greater fear of recurrence.(29) Discussion: Given the high tumor-free survival rates, esophagectomy was the standard treatment for BE patients with HGD and intramucosal EAC…”
ResultEndoscopic eradication of Barrett's esophagus
Wani, S. B., Sayana, H. P., & Sharma, P. (2009) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2009.07.026 · Cited by 42 · cited 1×
“Discussion: EMR plays a critical role as a part of the armamentarium for Barrett’s EET and has evolved into an important diagnostic/staging and therapeutic tool in the management of BE-related neoplasia patients.(3,59) The value of EMR as a diagnostic/staging tool is enhanced by the provision of larger and deeper tiss…”
BackgroundSelf-citationYachimski, P., Wani, S. B., Givens, T., Howard, E. F., Higginbotham, T., Price, A. S., Berman, K. H., Hosford, L., Menard-Katcher, P. A., Ozanne, E. M., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.03.017 · Cited by 16
Self-citation
Cited by
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, N. J., Falk, G. W., Iyer, P. G., Souza, R. F., Yadlapati, R. H., Sauer, B. G., & Wani, S. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001680 · Cited by 510
Self-citationASGE guideline on screening and surveillance of Barrett’s esophagus
Qumseya, B., Sultan, S., Bain, P., Jamil, L., Jacobson, B., Anandasabapathy, S., Agrawal, D., Buxbaum, J. L., Fishman, D. S., Gurudu, S. R., et al. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.05.012 · Cited by 437
Self-citation
Metadata
- Authors
- Wani, S., Qumseya, B., Sultan, S., Agrawal, D., Chandrasekhara, V., Harnke, B., Kothari, S., McCarter, M., Shaukat, A., Wang, A., Yang, J., & Dewitt, J.
- Venue
- Gastrointestinal Endoscopy
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 87
- Issue
- 4
- Pages
- 907-931.e9
- ISSN
- 0016-5107 (ISSN-L)
- OpenAlex
- W2787274608
- Cited by
- 170
- References
- 44
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.